

LYN-1604

Catalog No: tcsc0022180



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

2088939-99-3

Formula:

$C_{33}H_{43}Cl_2N_3O_2$

Pathway:

Autophagy

Target:

ULK

Purity / Grade:

>98%

Solubility:

DMSO : 100 mg/mL (171.05 mM; Need ultrasonic and warming)

Alternative Names:

LYN1604;LYN 1604

Observed Molecular Weight:

584.62


Product Description

LYN-1604 is a potent UNC-51-like kinase 1 (**ULK1**) agonist with an **EC₅₀** of 18.94 nM.

IC50 & Target: EC50: 18.94 nM (ULK1)^[1]

In Vitro: LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) agonist with an EC₅₀ of 18.94 nM in ADP-Glo™ kinase assay. The *in vitro* kinase assay reveals that the LYN-1604 increases the phosphorylation of mATG13 at ser318 in wild-type ULK1 transfected HEK-293T cells. It is found that LYN-1604-treated cells display a remarkable green fluorescence with MDC staining and the autophagy ratio is increased in a dose-dependent manne. It is also found that LYN-1604 induces remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II^[1].

In Vivo: Based on the results of tumor volume and weight, it is found that LYN-1604 can significantly inhibit the growth of xenograft MDA-MB-231 cells. The body weights of mice are stable, with no obvious distinctions between LYN-1604-treated and control mice. It also reveals that LYN-1604 induces remarkable autophagy *in vivo*^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!